Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. EUDA
EUDA logo

EUDA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.398
Open
0.393
VWAP
0.36
Vol
207.71K
Mkt Cap
13.60M
Low
0.326
Amount
75.58K
EV/EBITDA(TTM)
--
Total Shares
37.16M
EV
21.95M
EV/OCF(TTM)
--
P/S(TTM)
2.81
EUDA Health Holdings Limited is a health technology company. The Company operates a southeast Asian digital healthcare ecosystem. Its unified artificial intelligence platform assesses patients' medical history, triages conditions, digitally connects patients with clinicians, and predicts optimal treatment outcomes. Its holistic approach supports patients throughout all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. Its medical urgent care services provide healthcare assistance and medical evacuation to individual and corporate clients. Its property management service covers the management of properties, such as condominiums and shopping malls. Its services include e-triage, GP consult, e-medical certificates, and medical prescriptions. Its EUDA platform provides medical services from primary to post-surgery care and ongoing preventive healthcare for clients, regardless of the level of healthcare required.
Show More

Events Timeline

(ET)
2026-03-20
20:00:00
EUDA Health Holdings Ltd Trading Halted, News Pending
select
2026-03-04 (ET)
2026-03-04
09:20:00
EUDA Health Fully Repurchases and Cancels Warrant from Streeterville Capital
select
2026-01-13 (ET)
2026-01-13
08:00:00
EUDA Health Enters 6M RMB Convertible Loan Agreement with Shenzhen Inno
select
2026-01-07 (ET)
2026-01-07
06:10:00
EUDA Health Amends Warrant Agreement, Reduces Exercise Price to $4
select
2025-12-30 (ET)
2025-12-30
07:10:00
EUDA Health Launches Nationwide Stem Cell Extraction and Storage Platform in China
select
2025-12-29 (ET)
2025-12-29
07:10:00
EUDA Health to Launch EUDA Helixe 2.0 in January 2026
select
2025-12-23 (ET)
2025-12-23
07:10:00
EUDA Health Launches Stem Cell Therapy Platform in Shenzhen, China
select

News

Yahoo Finance
4.0
03-10Yahoo Finance
EUDA Health Price Target Cut to $2.75 by Analyst
  • Price Target Adjustment: Analyst William Gregozeski has lowered EUDA Health's price target from $6 to $2.75 while maintaining a Buy rating, reflecting a cautious outlook on future sales performance.
  • Sales Forecast Reduction: The expected sales of Helixe bottles in 2026 have been revised down from 105,000 to 50,000, resulting in a revenue estimate drop from $43.05 million to $27.23 million, indicating a significant weakening in market demand.
  • Dilutive Impact: The analyst highlights that the issuance of 12.5 million shares in late February has a dilutive effect on EPS estimates, which may undermine investor confidence in the company's profitability.
  • Capital Dynamics: EUDA Health's capital moves in 2026 include repurchasing and canceling the Streeterville warrant, raising $3.75 million to improve its financial position, demonstrating proactive measures in adjusting its capital structure.
Newsfilter
8.5
03-04Newsfilter
EUDA Health Holdings Fully Repurchases Warrant
  • Warrant Repurchase: EUDA Health Holdings fully repurchased and canceled the warrant issued to Streeterville Capital for a total of $125,000 on February 27, 2026, eliminating the potential issuance of 2 million new ordinary shares and enhancing the stability of the company's capital structure.
  • Strategic Focus: As a non-invasive healthcare provider focused on Singapore, Malaysia, and China, EUDA aims to become a market leader in the rapidly growing longevity sector, addressing the healthcare needs of over 1.8 billion people, particularly the 30% of the population that is aging rapidly.
  • Market Positioning: By offering innovative, accessible, and science-backed health solutions, EUDA is actively transforming regional healthcare from reactive treatment to proactive, longevity-focused care, further solidifying its market position in the Asia-Pacific region.
  • Business Diversification: In addition to healthcare services, EUDA operates a property management business in Singapore, demonstrating its strategic approach to diversification, which aims to enhance overall business resilience through multiple revenue streams.
NASDAQ.COM
9.5
01-08NASDAQ.COM
ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept
  • Clinical Trial Progress: ALX Oncology Holdings Inc. announced positive data from its Phase 2 trial of evorpacept for indolent B-cell non-Hodgkin lymphoma, leading to a 10.17% stock increase to $1.30, with detailed results set to be presented at the ASH Annual Meeting on December 7, 2025, potentially boosting investor confidence.
  • Sales Performance Surge: Globus Medical, Inc. reported preliminary unaudited Q4 2025 sales of approximately $823.2 million, a 25.2% year-over-year increase, with full-year sales expected to reach $2.936 billion, reflecting strong performance and growth potential in the medical device market.
  • Future Outlook: Globus Medical set its 2026 revenue guidance between $3.18 billion and $3.22 billion, with projected non-GAAP earnings per share ranging from $4.30 to $4.40, indicating confidence in future performance that may attract more investor interest.
  • Industry Developments: Acrivon Therapeutics, Inc. plans to release clinical data updates for ACR-368 and ACR-2316 on January 8, 2026, resulting in a 6.44% stock increase to $3.14, reflecting market optimism regarding its R&D progress, which could influence future financing and partnership opportunities.
Globenewswire
7.5
01-07Globenewswire
EUDA Health Holdings Lowers Warrant Exercise Price to $4
  • Warrant Amendment: EUDA has amended its agreement with Streeterville Capital to reduce the warrant exercise price from $6 to $4 per share, which is expected to enhance investor willingness to exercise the warrants, thereby improving the company's liquidity.
  • Forced Exercise Condition Adjustment: The minimum closing price required for a forced exercise has been lowered from $7.50 to $6.00, which may encourage more investors to exercise their warrants during market fluctuations, further optimizing the company's capital structure.
  • Strengthened Market Positioning: EUDA focuses on the non-invasive healthcare market in Singapore, Malaysia, and China, aiming to address the healthcare needs of over 1.8 billion people, positioning itself strategically in the rapidly growing longevity sector amid accelerating demographic shifts.
  • Business Diversification: In addition to healthcare, EUDA operates a property management business in Singapore, showcasing its capability to diversify across multiple sectors, aiming to enhance overall market competitiveness through varied business operations.
Globenewswire
3.5
2025-12-30Globenewswire
EUDA Launches Nationwide Stem Cell Extraction Platform, Supporting 200,000 Units Storage
  • Platform Launch: EUDA has launched a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, marking a significant advancement in its stem cell strategy aimed at enhancing service capabilities in emerging markets.
  • Partnerships Established: Collaborating with Shenzhen Inno Immune and Wuhan Kaien Hospital ensures cell processing and storage capabilities in Southern and Central China, with initial designed storage capacities of 50,000 and 200,000 units respectively, thereby enhancing clinical service coverage.
  • National Network Development: EUDA is building a network of approximately 200 clinical preparation and treatment clinics across more than 20 provinces through partnerships with Guangdong Wanhai Cell Biotechnology and Shunfeng Cold Chain Logistics, ensuring convenient access for patients to undergo stem cell extraction and subsequent treatments.
  • Strategic Vision: The CEO of EUDA stated that this platform will transform how regenerative medicine is accessed and delivered in China by integrating extraction, storage, and logistics into a comprehensive scalable infrastructure to meet the rapidly growing demands of the aging market.
Newsfilter
3.5
2025-12-30Newsfilter
EUDA Launches Nationwide Stem Cell Extraction and Storage Platform, Supporting 200,000 Patients
  • Platform Launch: EUDA has introduced a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China, marking a significant advancement in the company's stem cell strategy aimed at enhancing healthcare service capabilities in the Asia-Pacific region.
  • Partnerships Established: Collaborating with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital ensures cell processing and storage capabilities in Southern and Central China, with initial designed capacities of 50,000 and 200,000 patient cell units respectively, thereby enhancing clinical service coverage.
  • National Network Development: By partnering with Guangdong Wanhai Cell Biotechnology Co., Ltd. and Shunfeng Cold Chain Logistics Co., Ltd., EUDA has established a nationwide clinical access layer supporting a network of approximately 200 treatment clinics, ensuring convenient stem cell extraction and clinical delivery for patients.
  • Strategic Vision: EUDA's CEO stated that this platform will transform how regenerative medicine is accessed and delivered in China, creating an integrated ecosystem that connects extraction, storage, and clinical delivery to meet the demands of the rapidly growing aging market.

Valuation Metrics

The current forward P/E ratio for EUDA Health Holdings Ltd (EUDA.O) is 42.78, compared to its 5-year average forward P/E of -11.35. For a more detailed relative valuation and DCF analysis to assess EUDA Health Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.35
Current PE
42.78
Overvalued PE
17.28
Undervalued PE
-39.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.48
Undervalued EV/EBITDA
-9.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.21
Current PS
5.15
Overvalued PS
12.87
Undervalued PS
1.54

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top loosers today
Intellectia · 908 candidates
Region: USPrice Change Pct: <= $-3.00
Ticker
Name
Market Cap$
top bottom
OLMA logo
OLMA
Olema Pharmaceuticals Inc
1.70B
ORIC logo
ORIC
Oric Pharmaceuticals Inc
1.54B
RVPH logo
RVPH
Reviva Pharmaceuticals Holdings Inc
20.87M
EUDA logo
EUDA
EUDA Health Holdings Ltd
27.12M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
9.68M
COOK logo
COOK
Traeger Inc
84.24M
stocks under $1 bullish
Intellectia · 185 candidates
Price: <= $1.00Moving Average Relationship: PriceAboveMA20, PriceAboveMA5Macd: bullish
Ticker
Name
Market Cap$
top bottom
ENSC logo
ENSC
Ensysce Biosciences Inc
1.43M
KLTO logo
KLTO
Klotho Neurosciences Inc
35.15M
VEEA logo
VEEA
Veea Inc
21.68M
FMFC logo
FMFC
Kandal M Venture Ltd
7.94M
BYND logo
BYND
Beyond Meat Inc
371.93M
MMA logo
MMA
Mixed Martial Arts Group Ltd
14.62M

Whales Holding EUDA

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is EUDA Health Holdings Ltd (EUDA) stock price today?

The current price of EUDA is 0.3661 USD — it has decreased -8.28

What is EUDA Health Holdings Ltd (EUDA)'s business?

EUDA Health Holdings Limited is a health technology company. The Company operates a southeast Asian digital healthcare ecosystem. Its unified artificial intelligence platform assesses patients' medical history, triages conditions, digitally connects patients with clinicians, and predicts optimal treatment outcomes. Its holistic approach supports patients throughout all stages of care, including wellness and prevention, urgent care and emergencies, pre-existing conditions, and aftercare services. Its medical urgent care services provide healthcare assistance and medical evacuation to individual and corporate clients. Its property management service covers the management of properties, such as condominiums and shopping malls. Its services include e-triage, GP consult, e-medical certificates, and medical prescriptions. Its EUDA platform provides medical services from primary to post-surgery care and ongoing preventive healthcare for clients, regardless of the level of healthcare required.

What is the price predicton of EUDA Stock?

Wall Street analysts forecast EUDA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EUDA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is EUDA Health Holdings Ltd (EUDA)'s revenue for the last quarter?

EUDA Health Holdings Ltd revenue for the last quarter amounts to 104.28K USD, decreased -95.71

What is EUDA Health Holdings Ltd (EUDA)'s earnings per share (EPS) for the last quarter?

EUDA Health Holdings Ltd. EPS for the last quarter amounts to -0.51 USD, increased 750.00

How many employees does EUDA Health Holdings Ltd (EUDA). have?

EUDA Health Holdings Ltd (EUDA) has 117 emplpoyees as of March 22 2026.

What is EUDA Health Holdings Ltd (EUDA) market cap?

Today EUDA has the market capitalization of 13.60M USD.